Nebraska Methodist Health System
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nebraska Methodist Health System sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Nebraska Methodist Health System: 5 sponsored US clinical trials, 2 recruiting.
Nebraska Methodist Health System sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension in Pregnancy, with 2 trials.
Upper-quartile sponsor footprint
Nebraska Methodist Health System sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Postpartum Evaluation of Nifedipine and Enalapril for Hypertension
NCT07023003
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
NCT05309460
De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma
NCT04638465
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure
NCT07220902
Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site
NCT04880603
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Where Nebraska Methodist Health System enrollment is open (later-stage tilt)
2 recruiting of 5 indexed (40% open).
Phase mix: 3 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Hypertension in Pregnancy (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nebraska Methodist Health System: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Nebraska Methodist Health System sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Nebraska Methodist Health System page
5 registered trials is a research-attention snapshot, not an endorsement of Nebraska Methodist Health System or any single study.
- 2 of Nebraska Methodist Health System's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypertension in Pregnancy is the condition Nebraska Methodist Health System studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension in Pregnancy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nebraska Methodist Health System pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.